Rigel Pharmaceuticals Inc. (RIGL)

3.52
0.11 3.20
NASDAQ : Health Technology
Prev Close 3.41
Open 3.38
Day Low/High 3.28 / 3.54
52 Wk Low/High 2.28 / 4.71
Volume 3.10M
Avg Volume 2.23M
Exchange NASDAQ
Shares Outstanding 166.44M
Market Cap 534.28M
EPS -0.60
P/E Ratio 80.25
Div & Yield N.A. (N.A)
Astra, Rigel Arthritis Pill Posts Mixed Trial Results

Astra, Rigel Arthritis Pill Posts Mixed Trial Results

The future of the rheumatoid arthritis pill remains cloudy following trial results announced Friday.

3 Stocks Under $10 Making Big Moves

3 Stocks Under $10 Making Big Moves

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Stocks Under $10: Blossoming Biotech Play

Stocks Under $10: Blossoming Biotech Play

Portfolio manager David Peltier discusses a hot biotech stock with a promising clinical pipeline.

The Next Big Thing in Biotech: Pfizer

The Next Big Thing in Biotech: Pfizer

Senior columnist Adam Feuerstein says Pfizer is the next big thing in biotech.

Biotech Calendar: Key Dates for October

Biotech Calendar: Key Dates for October

Here's a list of October's potentially stock-moving biotech events.

Vertex Arthritis Pill Shines in Mid-Stage Study

Vertex Arthritis Pill Shines in Mid-Stage Study

Vertex moves ahead with late but competitive pill for rheumatoid arthritis, a $12 billion treatment market.

Rigel Stock Falls On Unusually High Volume (RIGL)

Rigel Stock Falls On Unusually High Volume (RIGL)

Rigel Pharmaceuticals (Nasdaq:RIGL) is trading at unusually high volume Thursday with 1.3 million shares changing hands. It is currently at 4.6 times its average daily volume and trading down 24 cents (-2.8%).

Rigel Pharmaceuticals Inc. Stock Downgraded (RIGL)

Rigel Pharmaceuticals Inc. Stock Downgraded (RIGL)

Rigel Pharmaceuticals (Nasdaq:RIGL) has been downgraded by TheStreet Ratings from from a hold to sell.

Brocade, Rigel, ARM: Early Volume Plays

Brocade, Rigel, ARM: Early Volume Plays

Several stocks trading under $10 were poised to move on above-average volume during Tuesday's session.

Rigel May Get $1.245B in Drug License Pact

Rigel May Get $1.245B in Drug License Pact

Rigel could receive $1.245 billion in a license agreement for its rheumatoid arthritis drug with AstraZeneca.

Analysts Name Top Biotech Stocks for 2010: BioBuzz

Sell-side firms release optimistic outlooks for the biotech sector.

Rigel Shares Rise On RBC Analyst Upgrade

Rigel Shares Rise On RBC Analyst Upgrade

Rigel Pharmaceuticals shares rise on RBC Capital Markets analyst upgrade

Bristol Licenses Arthritis Drug: BioBuzz

Bristol Licenses Arthritis Drug: BioBuzz

Worldwide deal involves privately held Alder BioTherapeutics

Rigel 3Q Loss Narrows On Lower Costs

Rigel Pharmaceuticals' 3rd-quarter loss narrows on lower stock, development costs

Galleon's Biotech Stock Holdings: BioBuzz

Galleon's Biotech Stock Holdings: BioBuzz

If the troubled hedge fund liquidates, it will sell biotech stocks.

Psst... These Drug Firms Are Getting Bought: BioBuzz

Psst... These Drug Firms Are Getting Bought: BioBuzz

Big Pharma is seeking deals with biotech, specialty pharma, analyst says

Rigel's R788 Drug Improves RA Symptoms

Rigel's R788 Drug Improves RA Symptoms

Rigel's oral medicine, R788, significantly improved the symptoms of rheumatoid arthritis patients in a study compared with a placebo, but as in previous studies high blood pressure emerged as a leading side effect.

New RA Data Could Be Magic Pill for Rigel

New data for Rigel's rheumatoid arthritis pill could ease safety fears and open doors for a lucrative deal.

Biotech Calendar: Key Clinical Trial Dates

A quick and dirty guide to upcoming clinical trial dates for drug and biotech companies.

Movers Roundup: Rigel Pharma, Mueller Water

Movers roundup: Rigel Pharma gains on arthritis drug potential, Mueller Water Products rises

Analyst: Rigel Arthritis Drug Poised To Compete

Analyst: Rigel Arthritis Drug Poised To Compete

Rodman & Renshaw analyst expects Rigel Pharmaceuticals arthritis drug to perform well

Rigel Falls on Drug-Deal Delays, Layoffs

Rigel Falls on Drug-Deal Delays, Layoffs

Rigel shares were falling after the small drug maker announced plans to cut its workforce and delay partnership plans for a key rheumatoid arthritis drug.

Single Drugmakers Seek Rich Partners

Single Drugmakers Seek Rich Partners

Scores of smaller biotech firms have unpartnered drugs in the pipeline, making them ripe for alliances or takeovers.

Health Winners & Losers: Genzyme

Sanofi-Aventis climbs, while Amylin falls.

Rigel Shares Tank on Arthritis Data (Update)

Shares of Rigel tanked late Monday, as the company presented data for experimental arthritis treatment R788.

Incyte's Rheumatoid Arthritis Pill Promising

An experimental pill from Incyte reduced symptoms in rheumatoid arthritis patients, according to results from a small phase II study presented Sunday.

Health Winners & Losers: Cell Genesys

The stock takes a beating after company ends late-stage trial of GVAX.

Biotech-Stock Mailbag: Genentech

Biotech-Stock Mailbag: Genentech

If Roche is serious about buying the company, it will need to do much better than $89 a share.

Feuerstein's Biotech-Stock Mailbag: Navigating the Sector Swoon

The pros see more trouble ahead.

Focus on Jobs Report

The January numbers will likely trigger a buying spike that will lift the major indices to new recovery highs.

TheStreet Quant Rating: D (Sell)